

Rosario Pivonello

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7004413/rosario-pivonello-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211
papers

9,700
citations

59
h-index

90
g-index

222
ext. papers

11,529
ext. citations

6.1
avg, IF

5.99
L-index

#	Paper	IF	Citations
211	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2664-72	5.6	291
210	Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2527-33	5.6	264
209	The Treatment of Cushing's Disease. <i>Endocrine Reviews</i> , 2015 , 36, 385-486	27.2	262
208	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 223-30	5.6	250
207	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 611-29	18.1	229
206	Dopamine receptor expression and function in corticotroph pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2452-62	5.6	210
205	Resistance to somatostatin analogs in acromegaly. <i>Endocrine Reviews</i> , 2011 , 32, 247-71	27.2	186
204	Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5256-61	5.6	169
203	Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. <i>European Journal of Endocrinology</i> , 2008 , 158, 623-30	6.5	160
202	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2003 , 148, 325-31	6.5	158
201	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2247-52	5.6	146
200	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012 , 167, 189-98	6.5	144
199	Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1919-24	5.6	138
198	LCI699, a potent 11 β hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1375-83	5.6	135
197	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , 2006 , 154, 467-77	6.5	133
196	Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 135-49, ix	5.5	132
195	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 20	51.1	128

194	Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3574-9	5.6	127
193	The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. <i>Reproductive Toxicology</i> , 2017 , 73, 105-127	3.4	119
192	The metabolic syndrome and cardiovascular risk in Cushing's syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 327-39, viii	5.5	117
191	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017 , 20, 46-62	4.3	116
190	Pathophysiology of diabetes mellitus in Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 77-84	5.6	116
189	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2017 , 56, 10-18	4	107
188	Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3746-56	5.6	107
187	High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3196-201	5.6	98
186	Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1674-83	5.6	97
185	Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1412-7	5.6	96
184	Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1551-7	5.6	94
183	The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. <i>Journal of Hypertension</i> , 2015 , 33, 44-60	1.9	92
182	Early vascular alterations in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3174-8	5.6	91
181	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S13-S21	6.5	90
180	Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1779-84	5.6	90
179	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 787-800	5.9	90
178	Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2016 , 19, 138-48	4.3	87
177	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003 , 58, 169-76	3.4	87

176	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015 , 9, 129	5.1	86
175	The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1088-93	5.6	86
174	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001 , 54, 515-24	3.4	84
173	Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1629-36	5.6	82
172	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , 2003 , 58, 302-8	3.4	82
171	The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1277-82	5.6	80
170	Smoke, alcohol and drug addiction and male fertility. <i>Reproductive Biology and Endocrinology</i> , 2018 , 16, 3	5	79
169	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014 , 81, 408-17	3.4	78
168	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000 , 52, 319-27	3.4	76
167	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 17-26	18.1	75
166	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1141-1147	5.2	74
165	Cardiovascular disease in Cushing's syndrome: heart versus vasculature. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 50-4	5.6	74
164	Cardiovascular consequences of early-onset growth hormone excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3097-104	5.6	74
163	Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 372-9	5.6	70
162	Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2076-80	5.6	69
161	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999 , 1, 115-20	4.3	69
160	Cabergoline plus lanreotide for ectopic Cushing's syndrome. <i>New England Journal of Medicine</i> , 2005 , 352, 2457-8	59.2	68
159	Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2007 , 157, 579-87	6.5	65

158	Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2639-46	5.6	64
157	Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4493-502	5.6	63
156	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , 2002 , 56, 153-8	3.4	62
155	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000 , 53, 53-60	3.4	60
154	Air pollution and female fertility: a systematic review of literature. <i>Reproductive Biology and Endocrinology</i> , 2018 , 16, 117	5	60
153	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007 , 51, 1381-91		59
152	Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 476-82	5.6	59
151	SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Societ�Italiana di Andrologia e Medicina della Sessualit�). <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1153-1157	5.2	58
150	Advances in the medical treatment of Cushing's syndrome. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 300-312	18.1	58
149	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 65-9	5.6	58
148	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1986-91	5.6	58
147	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , 2011 , 165, 713-21	6.5	57
146	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 48, 655-62	3.4	56
145	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 275-296	10.5	56
144	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 273-283	10.5	53
143	Bisphenol A: an emerging threat to female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020 , 18, 22	5	51
142	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. <i>Clinical Endocrinology</i> , 2012 , 76, 264-71	3.4	51
141	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009 , 71, 237-45	3.4	51

140	Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. <i>European Journal of Endocrinology</i> , 2007 , 157, 359-66	6.5	51
139	Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. <i>Journal of Endocrinological Investigation</i> , 1999 , 22, 860-5	5.2	50
138	Influence of Bisphenol A on Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2016 , 13,	4.6	50
137	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 847-875	18.1	48
136	Growth hormone, prolactin, and sexuality. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 782-94	5.2	47
135	Subclinical Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012 , 26, 497-505	6.5	47
134	Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 528-37	5.6	47
133	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 748-761	18.1	47
132	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014 , 170, 311-9	6.5	45
131	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000 , 53, 13-9	3.4	43
130	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017 , 24, 495-504	5.7	41
129	The role of vitamin D in male fertility: A focus on the testis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 285-305	10.5	41
128	Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2907-14	5.6	41
127	Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. <i>Reproductive BioMedicine Online</i> , 2016 , 33, 404-11	4	40
126	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 577-589	5.2	39
125	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2015 , 18, 604-12	4.3	39
124	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014 , 25, 441-6	5.3	38
123	The metabolic profile in active acromegaly is gender-specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E51-9	5.6	38

122	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015 , 50, 725-40	4	36
121	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 855-865	18.1	34
120	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 1017-30	5.2	34
119	Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4193-7	5.6	32
118	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , 2021 , 111, 1066-1085	5.6	31
117	Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 472-473	18.1	30
116	Six controversial issues on subclinical Cushing's syndrome. <i>Endocrine</i> , 2017 , 56, 262-266	4	29
115	The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 663-70	5.2	29
114	Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6616-22	5.6	29
113	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017 , 55, 872-884	4	28
112	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , 2001 , 4, 153-61	4.3	28
111	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. <i>Clinical Endocrinology</i> , 2000 , 52, 447-55	3.4	28
110	Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells. <i>Nutrients</i> , 2020 , 12,	6.7	27
109	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). <i>European Journal of Endocrinology</i> , 2014 , 171, 263-73	6.5	27
108	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014 , 46, 181-98	4	27
107	Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies. <i>BMC Surgery</i> , 2013 , 13, 57	2.3	26
106	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2012 , 15, 539-51	4.3	26
105	Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004 , 3, 309-18		26

104	Adverse events associated with somatostatin analogs in acromegaly. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1213-26	4.1	25
103	The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. <i>Endocrine</i> , 2017 , 55, 564-572	4	24
102	Cardiovascular alterations in adult GH deficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 25-34	6.5	24
101	Association between vitamin D and sperm parameters: Clinical evidence. <i>Endocrine</i> , 2017 , 58, 194-198	4	24
100	Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico-Andrologo survey. <i>Andrology</i> , 2019 , 7, 769-777	4.2	24
99	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 99-112	5.2	24
98	Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. <i>Progress in Brain Research</i> , 2010 , 182, 281-94	2.9	24
97	People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1391-1408	5.2	24
96	Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. <i>European Journal of Endocrinology</i> , 2013 , 168, 15-22	6.5	23
95	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020 , 11, 648	5.7	23
94	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , 2014 , 534, 282-5	3.8	22
93	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014 , 21, 601-13	5.7	22
92	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , 2001 , 4, 251-7	4.3	22
91	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects		22
90	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016 , 46, 54-65	3.5	22
89	Smoke, alcohol and drug addiction and female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020 , 18, 21	5	21
88	Impairment of bone status in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2275-80	5.6	21
87	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0186508	3.7	21

86	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence". <i>Endocrine</i> , 2019 , 64, 657-672	4	20
85	Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2009 , 32, 390-4	5.2	19
84	Early Vascular Alterations in Acromegaly		19
83	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. <i>Endocrine</i> , 2016 , 54, 516-523	4	19
82	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 9718-31	3.3	18
81	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <i>Bone</i> , 2016 , 86, 79-85	4.7	17
80	Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. <i>Frontiers in Endocrinology</i> , 2018 , 9, 383	5.7	17
79	Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 661-671	5.6	16
78	The safety of treatments for prolactinomas. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 503-12	4.1	16
77	Erectile Dysfunction is Common among Men with Acromegaly and is Associated with Morbidities Related to the Disease. <i>Journal of Sexual Medicine</i> , 2015 , 12, 1184-93	1.1	16
76	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. <i>Orphanet Journal of Rare Diseases</i> , 2015 , 10, 91	4.2	15
75	Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, 82-8	5.2	15
74	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2017 , 57, 314-325	4	14
73	Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1b. <i>Hormone Research in Paediatrics</i> , 2014 , 81, 55-62	3.3	14
72	Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2020 , 182, 207-217	6.5	14
71	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	14
70	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 654-656	18.1	13
69	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	13

68	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018 , 61, 118-124	4	13
67	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 497-506	5.2	13
66	Erectile dysfunction and cardiovascular risk: a review of current findings. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 155-164	2.5	12
65	The effect of FT500 Plus(□) on ovarian stimulation in PCOS women. <i>Reproductive Toxicology</i> , 2016 , 59, 40-4	3.4	12
64	Investigational therapies for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 955-63	5.9	12
63	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 49, 77-84	3.4	12
62	Acromegaly and Heart Failure. <i>Heart Failure Clinics</i> , 2019 , 15, 399-408	3.3	11
61	Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 154-9	5.2	11
60	Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. <i>Pituitary</i> , 2020 , 23, 203-211	4.3	11
59	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017 , 158, 1527-1532	4.8	10
58	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , 2017 , 56, 603-620	4	10
57	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021 , 24, 104-115	4.3	10
56	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019 , 9, 11695	4.9	9
55	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019 , 127, 695-709	2.1	9
54	Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2349-52	5.6	9
53	Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1613-1622	5.2	8
52	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , 2014 , 4, 329-329		8
51	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 57-65	10.5	8

50	The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 57-73	5.2	8
49	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 662865	5.7	8
48	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018 , 62, 663-680	4	7
47	ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome. <i>Pituitary</i> , 2020 , 23, 488-497	4.3	7
46	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2017 , 57, 539-543	4	6
45	Dopamine Agonists: From the 1970s to Today. <i>Neuroendocrinology</i> , 2019 , 109, 34-41	5.6	6
44	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001 , 54, 97-106	3.4	6
43	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2845-2847	5.2	6
42	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 99	4.2	6
41	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 932-7	5.2	5
40	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus		5
39	Medical Treatment of Cushing's Disease with Pasireotide. <i>European Endocrinology</i> , 2010 , 8, 99	3.4	4
38	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 267-79	5.2	4
37	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 595894	5.7	4
36	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. <i>Endocrine</i> , 2018 , 60, 65-72	4	4
35	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	3
34	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	3
33	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. <i>Frontiers in Endocrinology</i> , 2021 , 12, 747549	5.7	3

32	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2021 , 16, 159-174	4.1	3
31	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , 2021 , e13390	10.6	3
30	Is mortality in Cushing's disease reversible with remission?. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 551-2	18.1	2
29	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 557-567	1.1	2
28	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	2
27	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine Abstracts</i> ,		2
26	Subclinical male hypogonadism. <i>Minerva Endocrinology</i> , 2021 , 46, 252-261	2.5	2
25	Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1869-1878	5.2	2
24	How should patients with adrenal incidentalomas be followed up?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 352-4	18.1	1
23	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , 2001 , 4, 187-93	4.3	1
22	Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	1
21	Long-Term Complications of Hypercortisolism 2019 , 341-359		1
20	SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM). <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	1
19	Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs. <i>Veterinary Sciences</i> , 2021 , 8,	2.4	1
18	Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. <i>Endocrine Practice</i> , 2021 , 27, 471-477	3.2	1
17	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021 , 27, 1216-1224	3.2	1
16	Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.. <i>Scientific Reports</i> , 2022 , 12, 4368	4.9	1
15	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 874091	5.3	1

14	Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 930-932	18.1	0
13	Interferenti endocrini e funzione gonadica: focus su steroidogenesi testicolare e infertilità maschile. <i>L Endocrinologo</i> , 2022 , 23, 52	0	0
12	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021 , 151, 36-40	5	0
11	The dopaminergic control of Cushing's syndrome.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	0
10	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence [Authors' reply]. <i>Lancet Diabetes and Endocrinology, the</i> , 2022 , 10, 385-387	18.1	0
9	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 325-374	0.1	
8	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 1-50	0.1	
7	ACTH-Secreting Pituitary Tumors 2018 , 248-260		
6	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008 , 23, 1331-1331		
5	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 791633	5.7	
4	Clinical Case 1 2022 , 271-279		
3	Osteoporosis: May Doping Cause It?. <i>Trends in Andrology and Sexual Medicine</i> , 2020 , 163-173	0.5	
2	Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles. <i>Trends in Andrology and Sexual Medicine</i> , 2021 , 171-200	0.5	
1	Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions". <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016 , 155, 177	5.1	